Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective colon cancer therapy
Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum a...
Saved in:
| Published in | Drug delivery Vol. 29; no. 1; pp. 2633 - 2643 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Philadelphia
Taylor & Francis
31.12.2022
Taylor & Francis Ltd Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum albumin (BSA) as a lipid phase, surfactant, and stabilizer, respectively. The resulting nanocubosomes were characterized by measuring hydrodynamic particle size, particle size distribution (PSD), drug loading capacity (DL), encapsulation efficiency (EE), colloidal stability and drug release profile. We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. The prepared nanocubosomes exhibited a small hydrodynamic particle size (PS of 150 ± 10 nm in diameter) with nearly cubic shape and appropriate polydispersity index (PDI), enhanced drug loading capacity (LC of 6.82 ± 2.03% (Cur) and 9.65 ± 1.53% (TMZ), high entrapment efficiency (EE of 67.43 ± 2.16% (Cur) and 75.55 ± 3.25% (TMZ), pH-triggered drug release profile and higher colloidal stability in various physiological medium. Moreover, the nanocubosomes showed higher cellular uptake, in-vitro cytotoxicity and apoptosis compared to free drugs, curcumin and temozolomide, most likely because its small particle size. In addition, BSA-stabilized nanocubosomes were actively taken by aggressive colon cancer cells that over-expressed the albumin receptors and utilized BSA as nutrient source for their growth. In short, this study provides a new and simple strategy to improve the efficacy and simultaneously overawed the adaptive treatment tolerance in colon cancer. |
|---|---|
| AbstractList | Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum albumin (BSA) as a lipid phase, surfactant, and stabilizer, respectively. The resulting nanocubosomes were characterized by measuring hydrodynamic particle size, particle size distribution (PSD), drug loading capacity (DL), encapsulation efficiency (EE), colloidal stability and drug release profile. We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. The prepared nanocubosomes exhibited a small hydrodynamic particle size (PS of 150 ± 10 nm in diameter) with nearly cubic shape and appropriate polydispersity index (PDI), enhanced drug loading capacity (LC of 6.82 ± 2.03% (Cur) and 9.65 ± 1.53% (TMZ), high entrapment efficiency (EE of 67.43 ± 2.16% (Cur) and 75.55 ± 3.25% (TMZ), pH-triggered drug release profile and higher colloidal stability in various physiological medium. Moreover, the nanocubosomes showed higher cellular uptake, in-vitro cytotoxicity and apoptosis compared to free drugs, curcumin and temozolomide, most likely because its small particle size. In addition, BSA-stabilized nanocubosomes were actively taken by aggressive colon cancer cells that over-expressed the albumin receptors and utilized BSA as nutrient source for their growth. In short, this study provides a new and simple strategy to improve the efficacy and simultaneously overawed the adaptive treatment tolerance in colon cancer.Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum albumin (BSA) as a lipid phase, surfactant, and stabilizer, respectively. The resulting nanocubosomes were characterized by measuring hydrodynamic particle size, particle size distribution (PSD), drug loading capacity (DL), encapsulation efficiency (EE), colloidal stability and drug release profile. We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. The prepared nanocubosomes exhibited a small hydrodynamic particle size (PS of 150 ± 10 nm in diameter) with nearly cubic shape and appropriate polydispersity index (PDI), enhanced drug loading capacity (LC of 6.82 ± 2.03% (Cur) and 9.65 ± 1.53% (TMZ), high entrapment efficiency (EE of 67.43 ± 2.16% (Cur) and 75.55 ± 3.25% (TMZ), pH-triggered drug release profile and higher colloidal stability in various physiological medium. Moreover, the nanocubosomes showed higher cellular uptake, in-vitro cytotoxicity and apoptosis compared to free drugs, curcumin and temozolomide, most likely because its small particle size. In addition, BSA-stabilized nanocubosomes were actively taken by aggressive colon cancer cells that over-expressed the albumin receptors and utilized BSA as nutrient source for their growth. In short, this study provides a new and simple strategy to improve the efficacy and simultaneously overawed the adaptive treatment tolerance in colon cancer. Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum albumin (BSA) as a lipid phase, surfactant, and stabilizer, respectively. The resulting nanocubosomes were characterized by measuring hydrodynamic particle size, particle size distribution (PSD), drug loading capacity (DL), encapsulation efficiency (EE), colloidal stability and drug release profile. We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. The prepared nanocubosomes exhibited a small hydrodynamic particle size (PS of 150 ± 10 nm in diameter) with nearly cubic shape and appropriate polydispersity index (PDI), enhanced drug loading capacity (LC of 6.82 ± 2.03% (Cur) and 9.65 ± 1.53% (TMZ), high entrapment efficiency (EE of 67.43 ± 2.16% (Cur) and 75.55 ± 3.25% (TMZ), pH-triggered drug release profile and higher colloidal stability in various physiological medium. Moreover, the nanocubosomes showed higher cellular uptake, in-vitro cytotoxicity and apoptosis compared to free drugs, curcumin and temozolomide, most likely because its small particle size. In addition, BSA-stabilized nanocubosomes were actively taken by aggressive colon cancer cells that over-expressed the albumin receptors and utilized BSA as nutrient source for their growth. In short, this study provides a new and simple strategy to improve the efficacy and simultaneously overawed the adaptive treatment tolerance in colon cancer. Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs co-loaded nanocubosomal dispersion was prepared by modified emulsification method using glyceryl monooleate (GMO), pluronic F127 and bovine serum albumin (BSA) as a lipid phase, surfactant, and stabilizer, respectively. The resulting nanocubosomes were characterized by measuring hydrodynamic particle size, particle size distribution (PSD), drug loading capacity (DL), encapsulation efficiency (EE), colloidal stability and drug release profile. We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. The prepared nanocubosomes exhibited a small hydrodynamic particle size (PS of 150 ± 10 nm in diameter) with nearly cubic shape and appropriate polydispersity index (PDI), enhanced drug loading capacity (LC of 6.82 ± 2.03% (Cur) and 9.65 ± 1.53% (TMZ), high entrapment efficiency (EE of 67.43 ± 2.16% (Cur) and 75.55 ± 3.25% (TMZ), pH-triggered drug release profile and higher colloidal stability in various physiological medium. Moreover, the nanocubosomes showed higher cellular uptake, in-vitro cytotoxicity and apoptosis compared to free drugs, curcumin and temozolomide, most likely because its small particle size. In addition, BSA-stabilized nanocubosomes were actively taken by aggressive colon cancer cells that over-expressed the albumin receptors and utilized BSA as nutrient source for their growth. In short, this study provides a new and simple strategy to improve the efficacy and simultaneously overawed the adaptive treatment tolerance in colon cancer. |
| Author | Saeed Alqahtani, Saad Ali Khan, Barkat Iqbal, Haroon Khan, Muhammad Khalid Razzaq, Anam Ali Ahmad, Khalil Sultan, Muhammad H. Almoshari, Yosif |
| Author_xml | – sequence: 1 givenname: Yosif surname: Almoshari fullname: Almoshari, Yosif organization: Department of Pharmaceutics, College of Pharmacy, Jazan University – sequence: 2 givenname: Haroon surname: Iqbal fullname: Iqbal, Haroon organization: The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou – sequence: 3 givenname: Anam surname: Razzaq fullname: Razzaq, Anam organization: College of Pharmaceutical Sciences, Soochow University – sequence: 4 givenname: Khalil surname: Ali Ahmad fullname: Ali Ahmad, Khalil organization: The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou – sequence: 5 givenname: Muhammad Khalid surname: Khan fullname: Khan, Muhammad Khalid organization: Drug Delivery and Cosmetic Lab (DDCL), Gomal Center of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University – sequence: 6 givenname: Saad surname: Saeed Alqahtani fullname: Saeed Alqahtani, Saad organization: Pharmacy Practice Research Unit, College of Pharmacy, Jazan University – sequence: 7 givenname: Muhammad H. surname: Sultan fullname: Sultan, Muhammad H. organization: Department of Pharmaceutics, College of Pharmacy, Jazan University – sequence: 8 givenname: Barkat surname: Ali Khan fullname: Ali Khan, Barkat organization: Drug Delivery and Cosmetic Lab (DDCL), Gomal Center of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University |
| BookMark | eNqFkktvEzEUhUeoiD7gJyCNxIZNgp_jGSEhUHlVqsSme8tjXyeOPL7BM5MqbPjrOCRdtAtY2fI957PuveeyOkuYoKpeU7KkpCXvKFFUSSGWjDC2ZOWt4-2z6oJKRhdENOKs3ItmcRCdV5fjuCGEtJTJF9U5l51gkoqL6vdn2EHE7QBpqtHXySS0c48jDjDWFhcRjQNX34dpXbvZxNqkKViTLOTarIqrqOZs5yGkUnL1BAP-wohDcFB7zDV4D3YKOyi0iKk-eac1ZLPdv6yeexNHeHU6r6q7r1_urr8vbn98u7n-dLuwknfTglvOKGUULPSuA2VEo6j3BJTvCfOcNrZpWUeNUz3rZeMdg6Z30gtl-pbyq-rmiHVoNnqbw2DyXqMJ-u8D5pU2ufQVQbetFI741gEjwlNpnJVUSstUw62gfWF9OLK2cz-As2UG2cRH0MeVFNZ6hTvd8UY1khXA2xMg488ZxkkPYbQQo0mA86iZIoRTxlRXpG-eSDc451QmVVRSdJ1ilBfV-6PKZhzHDF7bMJkp4OH_EDUl-pAZ_ZAZfciMPmWmuOUT90Mr__N9PPpCKnsezD3m6PRk9hGzz2XLYdT834g_2afbqQ |
| CitedBy_id | crossref_primary_10_1016_j_prp_2024_155546 crossref_primary_10_1007_s00210_024_03104_9 crossref_primary_10_1016_j_ijbiomac_2023_126722 crossref_primary_10_1021_acs_inorgchem_4c02502 crossref_primary_10_1016_j_jddst_2023_105012 crossref_primary_10_1016_j_biopha_2022_113790 crossref_primary_10_1016_j_jddst_2024_105791 crossref_primary_10_1016_j_eurpolymj_2023_111877 crossref_primary_10_1007_s10876_024_02699_6 crossref_primary_10_1016_j_jsps_2024_102050 crossref_primary_10_1016_j_bbcan_2023_189011 crossref_primary_10_1515_znb_2022_0147 crossref_primary_10_1186_s12870_024_05525_3 crossref_primary_10_1007_s12668_024_01299_y crossref_primary_10_1080_09205063_2023_2177474 crossref_primary_10_3390_pharmaceutics16030431 crossref_primary_10_1080_03008207_2023_2235007 crossref_primary_10_1007_s12668_023_01270_3 crossref_primary_10_1016_j_colsurfb_2023_113526 crossref_primary_10_1038_s41598_024_82687_y crossref_primary_10_1080_08982104_2024_2410748 |
| Cites_doi | 10.1039/D2RA00742H 10.1016/j.colsurfb.2022.112505 10.1186/s12951-018-0392-8 10.1016/j.colsurfb.2015.01.027 10.1039/C5TB00248F 10.1016/j.jconrel.2016.01.018 10.3390/ijms20051033 10.1016/S1470-2045(11)70199-1 10.1016/j.ijpharm.2021.120670 10.1016/j.ijpharm.2007.03.036 10.1021/acsami.7b11423 10.1016/j.molliq.2015.12.007 10.1016/j.jconrel.2021.07.003 10.1016/j.saa.2021.119848 10.1016/j.colsurfa.2015.04.017 10.1186/s12885-018-4727-5 10.3390/molecules181215344 10.1007/s41048-018-0079-6 10.2147/NSA.S117018 10.1016/j.nano.2021.102369 10.1016/j.drup.2015.11.004 10.1007/s13346-020-00861-x 10.1016/j.jfoodeng.2019.03.005 10.1021/nn4017179 10.3109/10717544.2014.926574 10.3109/02652048.2014.885607 10.1016/j.bioadv.2022.213039 10.1007/s11060-018-03043-5 10.1016/j.jddst.2020.101663 10.1016/j.jfoodeng.2020.110258 10.3390/ma14123155 10.1002/adma.201503194 10.3390/molecules200814293 10.2147/IJN.S2.2.265 10.1039/D1BM01506K 10.1039/C6RA02912D 10.1016/j.ejmech.2020.112331 10.1016/j.cell.2012.03.031 10.1016/j.ijpharm.2021.120490 10.1016/j.ica.2022.120820 10.1016/j.ejpb.2013.04.018 10.3390/cancers6031769 10.1016/j.jconrel.2020.10.030 10.1080/10717544.2022.2073403 10.3390/ijms21051839 10.1016/j.jconrel.2019.04.036 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
| Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
| DBID | 0YH AAYXX CITATION 3V. 7X7 7XB 88I 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M2P PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1080/10717544.2022.2108938 |
| DatabaseName | Taylor & Francis Open Access CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Y. Almoshari et al |
| EISSN | 1521-0464 |
| EndPage | 2643 |
| ExternalDocumentID | oai_doaj_org_article_8854d0f8de204f15adc5155c2763c41b PMC9367652 10_1080_10717544_2022_2108938 2108938 |
| Genre | Research Article |
| GroupedDBID | --- 00X 0YH 29G 36B 4.4 53G 5GY 7X7 88I 8FI 8FJ ABDBF ABUWG ACGEJ ACGFS ACUHS ADBBV ADCVX ADRBQ ADXPE AENEX AFKRA AFKVX AJWEG ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ARJSQ AZQEC BABNJ BCNDV BENPR BLEHA BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P FYUFA GNUQQ GROUPED_DOAJ H13 HCIFZ HMCUK HZ~ M2P M4Z MK0 O9- OK1 P2P PIMPY PQQKQ PROAC RPM SV3 TDBHL TFDNU TFL TFW TUS UKHRP V1S ~1N AAYXX CITATION PHGZM PHGZT 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c539t-3c321121ecebd9e7a4671ff0e7fb02f316c68291ad7b2b56fd2e6bd5f47ab813 |
| IEDL.DBID | 7X7 |
| ISSN | 1071-7544 1521-0464 |
| IngestDate | Wed Aug 27 01:20:04 EDT 2025 Thu Aug 21 14:09:58 EDT 2025 Fri Jul 11 07:17:29 EDT 2025 Sun Jun 29 12:20:47 EDT 2025 Tue Jul 01 03:07:31 EDT 2025 Thu Apr 24 23:12:11 EDT 2025 Wed Dec 25 09:04:13 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-3c321121ecebd9e7a4671ff0e7fb02f316c68291ad7b2b56fd2e6bd5f47ab813 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contribute equally to this work. |
| OpenAccessLink | https://www.proquest.com/docview/2754997213?pq-origsite=%requestingapplication% |
| PMID | 35942514 |
| PQID | 2754997213 |
| PQPubID | 52922 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9367652 proquest_journals_2754997213 crossref_citationtrail_10_1080_10717544_2022_2108938 proquest_miscellaneous_2700312279 informaworld_taylorfrancis_310_1080_10717544_2022_2108938 doaj_primary_oai_doaj_org_article_8854d0f8de204f15adc5155c2763c41b crossref_primary_10_1080_10717544_2022_2108938 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-31 |
| PublicationDateYYYYMMDD | 2022-12-31 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | Philadelphia |
| PublicationPlace_xml | – name: Philadelphia |
| PublicationTitle | Drug delivery |
| PublicationYear | 2022 |
| Publisher | Taylor & Francis Taylor & Francis Ltd Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Ltd – name: Taylor & Francis Group |
| References | CIT0030 Poradowski D (CIT0034) 2022; 12 CIT0032 CIT0031 CIT0033 CIT0036 CIT0035 CIT-001 CIT0038 CIT0037 CIT0039 CIT0041 CIT0040 CIT0043 CIT0042 CIT0001 CIT0045 CIT0044 Kavya G (CIT0022) 2020; 56 CIT0003 CIT0047 CIT0002 CIT0046 CIT0005 CIT0049 CIT0004 CIT0048 CIT0007 CIT0006 CIT0051 CIT0010 CIT0012 CIT0011 Zhao X (CIT0050) 2014; 10 CIT0014 CIT0013 CIT0016 CIT0015 CIT0018 CIT0017 CIT0019 Karthikeyan R. (CIT0021) 2017; 5 CIT0020 CIT0023 CIT0025 CIT0024 CIT0027 CIT0026 CIT0029 CIT0028 |
| References_xml | – volume: 56 start-page: e17509 year: 2020 ident: CIT0022 publication-title: J. Pharm. Sci – ident: CIT0023 doi: 10.1039/D2RA00742H – ident: CIT0046 doi: 10.1016/j.colsurfb.2022.112505 – ident: CIT0033 doi: 10.1186/s12951-018-0392-8 – ident: CIT0001 doi: 10.1016/j.colsurfb.2015.01.027 – ident: CIT0014 doi: 10.1039/C5TB00248F – ident: CIT0029 doi: 10.1016/j.jconrel.2016.01.018 – ident: CIT0042 doi: 10.3390/ijms20051033 – ident: CIT0011 doi: 10.1016/S1470-2045(11)70199-1 – ident: CIT0036 doi: 10.1016/j.ijpharm.2021.120670 – ident: CIT0010 doi: 10.1016/j.ijpharm.2007.03.036 – ident: CIT0004 doi: 10.1021/acsami.7b11423 – ident: CIT0028 doi: 10.1016/j.molliq.2015.12.007 – ident: CIT0048 doi: 10.1016/j.jconrel.2021.07.003 – ident: CIT0045 doi: 10.1016/j.saa.2021.119848 – ident: CIT0035 doi: 10.1016/j.colsurfa.2015.04.017 – ident: CIT0037 doi: 10.1186/s12885-018-4727-5 – ident: CIT0025 doi: 10.3390/molecules181215344 – ident: CIT0031 doi: 10.1007/s41048-018-0079-6 – ident: CIT0005 doi: 10.2147/NSA.S117018 – ident: CIT0027 doi: 10.1016/j.nano.2021.102369 – ident: CIT0051 doi: 10.1016/j.drup.2015.11.004 – ident: CIT0024 doi: 10.1007/s13346-020-00861-x – ident: CIT0039 doi: 10.1016/j.jfoodeng.2019.03.005 – volume: 5 start-page: 104 year: 2017 ident: CIT0021 publication-title: Indian J Drugs – ident: CIT0047 doi: 10.1021/nn4017179 – volume: 12 issue: 7 year: 2022 ident: CIT0034 publication-title: Cell Lines Animal (Basel) – volume: 10 start-page: 257 year: 2014 ident: CIT0050 publication-title: IJN – ident: CIT0019 doi: 10.3109/10717544.2014.926574 – ident: CIT0043 doi: 10.3109/02652048.2014.885607 – ident: CIT-001 doi: 10.1016/j.bioadv.2022.213039 – ident: CIT0040 doi: 10.1007/s11060-018-03043-5 – ident: CIT0012 doi: 10.1016/j.jddst.2020.101663 – ident: CIT0020 doi: 10.1016/j.jfoodeng.2020.110258 – ident: CIT0017 doi: 10.3390/ma14123155 – ident: CIT0006 doi: 10.1002/adma.201503194 – ident: CIT0007 doi: 10.3390/molecules200814293 – ident: CIT0013 doi: 10.2147/IJN.S2.2.265 – ident: CIT0049 doi: 10.1039/D1BM01506K – ident: CIT0015 doi: 10.1039/C6RA02912D – ident: CIT0038 doi: 10.1016/j.ejmech.2020.112331 – ident: CIT0026 doi: 10.1016/j.cell.2012.03.031 – ident: CIT0002 doi: 10.1016/j.ijpharm.2021.120490 – ident: CIT0044 doi: 10.1016/j.ica.2022.120820 – ident: CIT0030 doi: 10.1016/j.ejpb.2013.04.018 – ident: CIT0016 doi: 10.3390/cancers6031769 – ident: CIT0018 doi: 10.1016/j.jconrel.2020.10.030 – ident: CIT0041 doi: 10.1080/10717544.2022.2073403 – ident: CIT0003 doi: 10.3390/ijms21051839 – ident: CIT0032 doi: 10.1016/j.jconrel.2019.04.036 |
| SSID | ssj0008125 |
| Score | 2.4234107 |
| Snippet | Current research aimed to develop nanocubosomes co-loaded with dual anticancer drugs curcumin and temozolomide for effective colon cancer therapy. Drugs... |
| SourceID | doaj pubmedcentral proquest crossref informaworld |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 2633 |
| SubjectTerms | Apoptosis Cancer therapies colon cancer Colorectal cancer curcumin Nanocubosomes Particle size temozolomide therapy |
| SummonAdditionalLinks | – databaseName: Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADB6hnrggniJQ0CChnpo288rjCIiqQgL1sEi9jeYpVuomaHdz2F7469iZZLvhsheu45kkjj32OLE_E_LRGKsMiy7n0otc1kXMrS-KvCkEj8GWzA3lY99_lNc_5bdbdXvQ6gtzwhI8cHpxl3WtpC9i7QMvZGTKeIddSRyHjeEks2h9wedNwdRog8FtqZRtyHKEeJtqd-riEsdwCGJDzi8g4gGPXc-80gDe_w906ewAOk-fPPBHV0_Jk_EgST8lBp6RR6F9Ts5uEhL17pwuHgqrNuf0jN48YFTvXpA_B8lCtIu0NW3netttulXYUNfld53xwVP8TEuxXIuCBNBiurCmBsuxYFa_dv1q2QLJU8zYvYeLr5Y-UGCIpkQRsKUU79nScW2q99q9JIurr4sv1_nYiyF3SjTbXDgBoSJnwQXrm1AZMLAsxiJU0RY8Cla6suYNM76y3Koyeh5K61WUlbE1E6_ISdu14TWhFRe2kZz7AETZlBAhQxRnlZDeutLxjMhJFNqNOOXYLuNOsxHOdJKgRgnqUYIZudgv-52AOo4t-Ixy3k9GnO1hALRPj9qnj2lfRppDLdHb4TNLTD1RtDjyAKeTSunRcGw0rzBgh7BcZOTDngxbHv_jmDZ0Pc5BU4zQjxmpZqo4Y2ZOaZe_BvDwBiH6FH_zP7h_Sx4jQwn38pScbNd9eAdntK19P2zHv6eZNsg priority: 102 providerName: Directory of Open Access Journals – databaseName: Taylor & Francis Open Access dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagXLggniJQkJFQT00Vv_I4AqJaIYF6WCQ4WX7CSt2k2mwOy6V_vTN5bDdIqAdOUTJ2YmvGMx5n5htC3htjlWHRpVx6kcoyi6n1WZZWmeAx2Jy5Pn3s67d88V1--aGmaMJ2DKtEHzoOQBG9rsbFbWw7RcTBFXwQJfFEhPMz8FnA5pb3yQOwxBkWMch-LvbKGOyXGsIOWYp9piSef71mZp56FP-_MExnO9F5HOWBYTp_TB6NO0r6YRCBJ-ReqJ-Sk4sBknp3Spe3GVbtKT2hF7dg1btn5Pogaog2kdamblxnm7ZZh5a6Jr1sjA-e4nktxbwtCqxA1enChhrMy4JW3cZ161UNJE8xdPcPvHy98oHChOgQMQJKleI3azr2HRK_ds_J8vzz8tMiHYsypE6JapsKJ8Bn5Cy4YH0VCgOalsWYhSLajEfBcpeXvGLGF5ZblUfPQ269irIwtmTiBTmqmzq8JLTgwlaScx-AKKscXGVw56wS0luXO54QObFCuxGwHOtmXGo24ppOHNTIQT1yMCFn-25XA2LHXR0-Ip_3jRFwu3_QbH7pcf3qslTSZ7H0gWcyMmW8w-I4joN-dpLZhFSHUqK3_XlLHIqjaHHHAI4nkdKjBmk1L9BzB_9cJOTdngxrH3_omDo0HbZBnYwYkAkpZqI4m8ycUq9-9yjiFWL1Kf7qPwb-mjzE2wH38pgcbTddeAN7tK1926_CGzw7M-k priority: 102 providerName: Taylor & Francis |
| Title | Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective colon cancer therapy |
| URI | https://www.tandfonline.com/doi/abs/10.1080/10717544.2022.2108938 https://www.proquest.com/docview/2754997213 https://www.proquest.com/docview/2700312279 https://pubmed.ncbi.nlm.nih.gov/PMC9367652 https://doaj.org/article/8854d0f8de204f15adc5155c2763c41b |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEF7R9sIF8RQpJVok1FO39T78OiGKWkVIVBEKUjhZ-4RIjV3i-BAu_evdsddJzIFe9-GHZnZ2v9mZbxD6KKWKJXWaMGE4EVnkiDJRRPKIM2dVQnWbPvbtJpn8EF_n8Tw43OoQVtnbxNZQm0qDj_yCpYBkPF7hn-7-EKgaBberoYTGAToC6jLQ6nS-BVx-t2uLrnqEQwkQvfUZPFl0AW3Q5BEiY-ce9_h9OxvsTS2F_z8EpoNj6DCIcm9Xun6OnoXjJP7cyf8FemLLl-h02vFRb87wbJdeVZ_hUzzdMVVvXqH7vZAhXDlcyrLSjarqamlrrCtyW0ljDQZnLYakLezlAHZT2xWWkJTlRzUr3SwXpe8yGOJ2__qHLxfGYv9DuAsX8RYVwztLHOZ2WV-b12h2fTX7MiGhIgPRMc_XhGvuASOjVltlcptKb2apc5FNnYqY4zTRScZyKk2qmIoTZ5hNlImdSKXKKH-DDsuqtG8RThlXuWDMWN8p8sTjZI_lVMyFUTrRbIREL4pCB7ZyKJpxW9BAatpLsAAJFkGCI3S-nXbX0XU8NuES5LwdDGzbbUO1-lWExVtkWSxM5DJjWSQcjaXRUBlHM2-ctaBqhPJ9LSnWrbPFdZVRCv7IB5z0KlUE81EXO2UfoQ_bbr_w4TZHlrZqYAwYZCCAHKF0oIqDnxn2lIvfLYV4DkR9MTv-_8vfoafwqR2v5Qk6XK8a-96fwdZqjA6in5Nxu9zG6Ojy6mb6fdz6Mx4A0l4yLQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbhQxELVCOMAFsYqGAEaCnNJJe-ntgBBbNCGLchikuVntLYyU6Q6zCA0Xvoh_pKqXmWkO5JSry-5FVS772VWvCHlTFDoumDchl1aEMot8qG0UhXkkuHc6YaZOHzs9Swbf5NdRPNoif7pcGAyr7Hxi7ahtZfCM_ICniGQAr4j3Vz9CrBqFt6tdCY3GLI7d8idAttm7o8-g37ecH34ZfhqEbVWB0MQin4fCCAA9nDnjtM1dWoCrYN5HLvU64l6wxCQZz1lhU811nHjLXaJt7GVa6IwJeOwtchvW3QixXjpa4TtYXOsaryBgIfLKdQlDWXSAbdgEgJTzfYBZsE3IekthXTHgH77U3q63H7O5sQge3if32t0r_dCY2wOy5cqHZPe8ob9e7tHhOptrtkd36fmaGHv5iPzeiFCiladlUVZmoatZNXEzaqrwsiqssxTPhinmiFFQO7pp46a0wBww6LWYmsVkXILIUgwT_gUPn4yto_BDtIlOAQdO8Z0lbcc2SWbLx2R4E6p6QrbLqnRPCU250Lnk3DoQyjwBWA7QUcdCWm0SwwMiO1Uo05KjY42OS8VaDtVOgwo1qFoNBmR_NeyqYQe5bsBH1POqM5J71w3V9EK1vkJlWSxt5DPreCQ9iwtrsBCP4bAWGMl0QPJNK1Hz-mzHN4VYlLjmA3Y6k1Ktt5qp9dwKyOuVGPwMXh4VpasW2Af9P_JNBiTtmWLvZ_qScvy9ZizPkRcw5s_-__JX5M5geHqiTo7Ojp-Tu_jZDaXmDtmeTxfuBWz_5vplPekoUTc8yf8Cnb9r9Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXxFMsFDAS9NRU8SuPAwegrLYUqj0sUjlZ8QtW6ibVPoSWC3-Jn8hMHtsNEuoB9RQpYye2xvnG48x8Q8irojCqYMFGXDoRySwOkXFxHOWx4MGbhNk6fezzaTL6Ij-eqbMd8rvLhcGwSvShQ0MUUWM1ftwXLnQRcXAFH0RJPBHh_BB8FrC5WRtXeeLXP8BrW7w5PgIVv-Z8-GHyfhS1hQUiq0S-jIQV4Pdw5q03LvdpAWjBQoh9GkzMg2CJTTKes8KlhhuVBMd9YpwKMi1MxgQ89ga5qeC1WCwi_jraYD-YS9VEObIIh9jlDP1r1D1rWBcN-Isytbfx7YdtbtnB4V1yp93A0rfNirtHdnx5n-yPGwbs9QGdXCZ0LQ7oPh1fcmOvH5BfW0FKtAq0LMrKrky1qGZ-QW0VnVeF847i8TDFNDEKmkektn5OC0wDg1aruV3NpiWIHMVI4Z_w8NnUeQoTok2ACmA4xXeWtO3b5JmtH5LJdajqEdktq9I_JjTlwuSSc-dBKPMEPHPwHo0S0hmbWD4gslOFti0_OpbpONespVHtNKhRg7rV4IAcbrpdNAQhV3V4h3reNEZ-7_pGNf-mW7jQWaaki0PmPI9lYKpwFmvxWA7mwEpmBiTfXiV6WR_vhKYWixZXDGCvW1K6BayF5ikeFKSciQF5uRED1OD_o6L01QrboAlAyskBSXtLsTeZvqScfq9Jy3OkBlT8yX8M_AW5NT4a6k_HpydPyW2UNIybe2R3OV_5Z7A7XJrn9QdJib5mAPgDrKJxCA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+nanocubosomes+co-loaded+with+dual+anticancer+agents+curcumin+and+temozolomide+for+effective+Colon+cancer+therapy&rft.jtitle=Drug+delivery&rft.au=Almoshari%2C+Yosif&rft.au=Iqbal%2C+Haroon&rft.au=Razzaq%2C+Anam&rft.au=Ali+Ahmad%2C+Khalil&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis&rft.issn=1071-7544&rft.eissn=1521-0464&rft.volume=29&rft.issue=1&rft.spage=2633&rft.epage=2643&rft_id=info:doi/10.1080%2F10717544.2022.2108938&rft_id=info%3Apmid%2F35942514&rft.externalDocID=PMC9367652 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-7544&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-7544&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-7544&client=summon |